|
Jun 5
|
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
|
|
Jun 3
|
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield
|
|
Jun 3
|
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
|
|
Jun 2
|
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
|
|
May 22
|
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT
|
|
May 14
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
May 14
|
Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00
|
|
Apr 21
|
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
|
|
Mar 13
|
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
|
|
Mar 4
|
ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 3
|
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
|
|
Feb 28
|
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
|
|
Feb 13
|
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
|
|
Dec 30
|
High Growth Tech Stocks to Watch in December 2024
|